<p>Biodesix, Inc.（纳斯达克代码：BDSX - 获取免费报告）在一月份的空头头寸显著增长。截至 1 月 15 日，空头头寸总计为 483,591 股，比 12 月 31 日的 80,722 股增长了 499.1%。根据平均交易量 7,865,756 股，目前的空头头寸比率为 0.1 天。目前，公司 8.7% 的股票被卖空。</p>
<h2>Biodesix 价格表现</h2>
<p>BDSX 的股票在周三开盘价为 11.08 美元。该公司的 50 日移动平均线为 7.75 美元，200 日移动平均线为 7.73 美元。公司的债务与股本比率为 41.11，流动比率为 1.84，速动比率为 1.84。该公司的市值为 8815 万美元，市盈率为-1.99，贝塔值为 0.60。Biodesix 的 52 周低点为 3.44 美元，52 周高点为 21.60 美元。</p>
<p>Biodesix（纳斯达克代码：BDSX - 获取免费报告）最后一次公布季度财报是在 11 月 3 日，报告显示该季度每股收益为（1.16 美元），超出分析师一致预期的（1.60 美元）0.44 美元。该季度的营业收入为 2177 万美元，而分析师预期为 2098 万美元。Biodesix 的净利润率为-49.31%，股本回报率为-504.41%。股票分析师预测 Biodesix 在当前年度的每股收益为-0.35 美元。</p>
<h2>分析师评级调整</h2>
<p>多家券商最近对 BDSX 发表了评论。华尔街 Zen 在 11 月 8 日的研究报告中将 Biodesix 的评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 12 月 22 日的研究报告中重申了对 Biodesix 的 “卖出（e+）” 评级。四位投资分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 32.50 美元。</p>
<p><strong>查看我们对 BDSX 的最新分析</strong></p>
<h2>内部人士买卖情况</h2>
<p>在其他新闻中，董事 Jack W. Schuler 在 1 月 26 日的交易中购买了 20,000 股公司的股票。每股购买价格为 11.80 美元，总价值为 236,000.00 美元。购买后，该董事直接持有公司 1,563,210 股股票，价值为 18,445,878 美元。这笔交易代表其持股增加了 1.30%。该交易已在 SEC 的备案中披露，您可以通过此链接访问。在过去一个季度，内部人士购买了 182,465 股公司股票，价值为 2,084,616 美元，并出售了 2,247 股，价值为 18,154 美元。公司内部人士持有 30.10% 的股票。</p>
<h2>机构投资者对 Biodesix 的看法</h2>
<p>多家机构投资者最近调整了对 BDSX 的持股。阿伯丁集团在第四季度购买了 Biodesix 的新头寸，价值约为 1,784,000 美元。XTX Topco Ltd 在第二季度将其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 现在拥有 205,647 股公司股票，价值 58,000 美元，此前在上个季度又购买了 102,494 股。甲骨文投资管理公司在第三季度收购了 Biodesix 的新头寸，价值 113,000 美元。最后，千禧管理公司在第三季度购买了 Biodesix 的新头寸，价值 113,000 美元。机构投资者持有公司 20.96% 的股票。</p>
<h2>关于 Biodesix</h2>
<p>（获取免费报告）</p>
<p>Biodesix, Inc 是一家商业阶段的分子诊断公司，总部位于科罗拉多州博尔德，开发和提供基于血液的检测，以改善肺部疾病的诊断和管理，包括肺癌。该公司整合了先进的蛋白质组学和最近的基因组技术，提供旨在指导临床决策的非侵入性检测解决方案。Biodesix 运营着一家 CLIA 认证和 CAP 认可的实验室，能够大规模处理患者样本并保持严格的质量标准。</p>
<p>该公司的旗舰产品 VeriStrat®是一种蛋白质组学检测，将非小细胞肺癌患者分层为更可能从特定疗法中受益的组别。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 Biodesix 更好</li>
<li>美国的下一个权力举动从地下开始</li>
<li>您的签名缺失 - 请在为时已晚之前采取行动</li>
<li>紧急：特朗普刚刚引发了人工智能的最大干扰</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>在周一上午 9:30 购买这只股票！</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Biodesix 吗？</h2>
<p>在您考虑 Biodesix 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Biodesix 并不在名单上。</p>
<p>虽然 Biodesix 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BDSX

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

基因免疫&健康关怀 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

生物科技 ETF - VanEck Vectors

<p>Biodesix, Inc.（纳斯达克代码：BDSX）在短期空头头寸方面经历了剧烈增长，1 月份上涨了 499.1%，总计达到 483,591 股。目前，该股票的空头比例为 8.7%，根据平均交易量 7,865,756 股计算，覆盖天数比率为 0.1 天。该公司的股票开盘价为 11.08 美元，市值为 8815 万美元，市盈率为-1.99。最近的分析师评级显示共识为 “适度买入”，目标价为 32.50 美元。内部人士近期也积极行动，购买了大量股份</p>

<p>Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totaling 483,591 shares, a growth of 499.1% from the December 31st total of 80,722 shares. Based on an average trading volume of 7,865,756 shares, the short-interest ratio is presently 0.1 days. Currently, 8.7% of the company's stock are sold short. Currently, 8.7% of the company's stock are sold short. Based on an average trading volume of 7,865,756 shares, the short-interest ratio is presently 0.1 days.</p>
<div class="lb-trans"><p>Biodesix, Inc.（纳斯达克代码：BDSX - 获取免费报告）在一月份的空头头寸显著增长。截至 1 月 15 日，空头头寸总计为 483,591 股，比 12 月 31 日的 80,722 股增长了 499.1%。根据平均交易量 7,865,756 股，目前的空头头寸比率为 0.1 天。目前，公司 8.7% 的股票被卖空。</p>
</div><h2>Biodesix Price Performance</h2>
<div class="lb-trans"><h2>Biodesix 价格表现</h2>
</div><p>Shares of BDSX opened at $11.08 on Wednesday. The company's 50-day moving average is $7.75 and its 200-day moving average is $7.73. The company has a debt-to-equity ratio of 41.11, a current ratio of 1.84 and a quick ratio of 1.84. The firm has a market capitalization of $88.15 million, a PE ratio of -1.99 and a beta of 0.60. Biodesix has a fifty-two week low of $3.44 and a fifty-two week high of $21.60.</p>
<div class="lb-trans"><p>BDSX 的股票在周三开盘价为 11.08 美元。该公司的 50 日移动平均线为 7.75 美元，200 日移动平均线为 7.73 美元。公司的债务与股本比率为 41.11，流动比率为 1.84，速动比率为 1.84。该公司的市值为 8815 万美元，市盈率为-1.99，贝塔值为 0.60。Biodesix 的 52 周低点为 3.44 美元，52 周高点为 21.60 美元。</p>
</div><p>Biodesix (NASDAQ:BDSX - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) EPS for the quarter, beating analysts' consensus estimates of ($1.60) by $0.44. The business had revenue of $21.77 million for the quarter, compared to analyst estimates of $20.98 million. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. Equities analysts forecast that Biodesix will post -0.35 EPS for the current year.</p>
<div class="lb-trans"><p>Biodesix（纳斯达克代码：BDSX - 获取免费报告）最后一次公布季度财报是在 11 月 3 日，报告显示该季度每股收益为（1.16 美元），超出分析师一致预期的（1.60 美元）0.44 美元。该季度的营业收入为 2177 万美元，而分析师预期为 2098 万美元。Biodesix 的净利润率为-49.31%，股本回报率为-504.41%。股票分析师预测 Biodesix 在当前年度的每股收益为-0.35 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of brokerages have recently commented on BDSX. Wall Street Zen raised shares of Biodesix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 8th. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Biodesix in a research report on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $32.50.</p>
<div class="lb-trans"><p>多家券商最近对 BDSX 发表了评论。华尔街 Zen 在 11 月 8 日的研究报告中将 Biodesix 的评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 12 月 22 日的研究报告中重申了对 Biodesix 的 “卖出（e+）” 评级。四位投资分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “适度买入”，共识目标价为 32.50 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on BDSX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 BDSX 的最新分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人士买卖情况</h2>
</div><p>In other news, Director Jack W. Schuler purchased 20,000 shares of the company's stock in a transaction on Monday, January 26th. The shares were purchased at an average price of $11.80 per share, with a total value of $236,000.00. Following the purchase, the director directly owned 1,563,210 shares of the company's stock, valued at $18,445,878. This trade represents a 1.30% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have acquired 182,465 shares of company stock valued at $2,084,616 and have sold 2,247 shares valued at $18,154. Corporate insiders own 30.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Jack W. Schuler 在 1 月 26 日的交易中购买了 20,000 股公司的股票。每股购买价格为 11.80 美元，总价值为 236,000.00 美元。购买后，该董事直接持有公司 1,563,210 股股票，价值为 18,445,878 美元。这笔交易代表其持股增加了 1.30%。该交易已在 SEC 的备案中披露，您可以通过此链接访问。在过去一个季度，内部人士购买了 182,465 股公司股票，价值为 2,084,616 美元，并出售了 2,247 股，价值为 18,154 美元。公司内部人士持有 30.10% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Biodesix</h2>
<div class="lb-trans"><h2>机构投资者对 Biodesix 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of BDSX. Aberdeen Group plc bought a new position in shares of Biodesix during the fourth quarter worth approximately $1,784,000. XTX Topco Ltd grew its stake in shares of Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock worth $58,000 after buying an additional 102,494 shares during the last quarter. Oracle Investment Management Inc. acquired a new position in shares of Biodesix during the third quarter worth $113,000. Finally, Millennium Management LLC bought a new position in shares of Biodesix in the 3rd quarter valued at $113,000. Institutional investors own 20.96% of the company's stock.</p>
<div class="lb-trans"><p>多家机构投资者最近调整了对 BDSX 的持股。阿伯丁集团在第四季度购买了 Biodesix 的新头寸，价值约为 1,784,000 美元。XTX Topco Ltd 在第二季度将其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 现在拥有 205,647 股公司股票，价值 58,000 美元，此前在上个季度又购买了 102,494 股。甲骨文投资管理公司在第三季度收购了 Biodesix 的新头寸，价值 113,000 美元。最后，千禧管理公司在第三季度购买了 Biodesix 的新头寸，价值 113,000 美元。机构投资者持有公司 20.96% 的股票。</p>
</div><h2>About Biodesix</h2>
<div class="lb-trans"><h2>关于 Biodesix</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.</p>
<div class="lb-trans"><p>Biodesix, Inc 是一家商业阶段的分子诊断公司，总部位于科罗拉多州博尔德，开发和提供基于血液的检测，以改善肺部疾病的诊断和管理，包括肺癌。该公司整合了先进的蛋白质组学和最近的基因组技术，提供旨在指导临床决策的非侵入性检测解决方案。Biodesix 运营着一家 CLIA 认证和 CAP 认可的实验室，能够大规模处理患者样本并保持严格的质量标准。</p>
</div><p>The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.</p>
<div class="lb-trans"><p>该公司的旗舰产品 VeriStrat®是一种蛋白质组学检测，将非小细胞肺癌患者分层为更可能从特定疗法中受益的组别。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Biodesix</li>
<li>America's Next Power Move Starts Underground</li>
<li>Your Signature Is Missing – Act Before It’s Too Late</li>
<li>URGENT: Trump Just Triggered AI’s Biggest Disruption Yet</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>Buy This Stock at 9:30 AM on MONDAY!</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Biodesix 更好</li>
<li>美国的下一个权力举动从地下开始</li>
<li>您的签名缺失 - 请在为时已晚之前采取行动</li>
<li>紧急：特朗普刚刚引发了人工智能的最大干扰</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>在周一上午 9:30 购买这只股票！</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Biodesix Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Biodesix 吗？</h2>
</div><p>Before you consider Biodesix, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Biodesix 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Biodesix 并不在名单上。</p>
</div><p>While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Biodesix 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Increases By 499.1%

Market Beat

Biodesix

Biodesix 公司（NASDAQ 代码：BDSX）的空头头寸增加了 499.1%